Bevacizumab plus irinotecanbased therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimens

Cancer Investigation

Volumn 28, Issue 1, 2010, Pages 33-37

  Yildiz, Ramazan ^a   Buyukberber, Suleyman ^a   Uner, Aytug ^a   Yamac, Deniz ^a   Coskun, Ugur ^a   Kaya, Ali Osman ^a   Ozturk, Banu ^a   Yaman, Emel ^a   Benekli, Mustafa ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

Bevacizumab; Irinotecan; Metastatic colorectal cancer; Oxaliplatin resistant

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; OXALIPLATIN; UFT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ABSCESS; ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERTENSION; INTESTINE PERFORATION; LIVER METASTASIS; LUNG METASTASIS; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PERIRECTAL ABSCESS; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RECTUM DISEASE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; VEIN THROMBOSIS; ADJUVANT CHEMOTHERAPY; COLORECTAL TUMOR; DISEASE COURSE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; TIME; TREATMENT FAILURE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT FAILURE;

EID: 72449179365     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357900802562996     Document Type: Article

References (23)

1. Cassidy, J.; Tabernero, J.; Twelves, C.; Brunet, R.; Butts, C.; Conroy, T.; Debraud, F.; Figer, A.; Grossmann, J.; Sawada, N.; Scḧ offski, P.; Sobrero, A.; Van Cutsem, E. Xelox (capecitabine plus oxaliplatin): active first-line therapy for patients withmetastatic colorectal cancer. J Clin Oncol 2004, 22(11), 2084-2091.
2. Yaman, E.; Uner, A.; Er, O.; Coskun, U.; Buyukberber, S.; Dikilitas, M.; Polat, M.; Yamac, D.; Kaya, A.O.; Yildiz, R.; Ozturk, B.; Benekli, M. Capecitabine plus oxaliplatin (Xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer. Med Oncol 2007, 24(4), 431-435.
3. Goldberg, R.M.; Sargent, D.J.; Morton, R.F.; Fuchs, C.S.; Ramanathan, R.K.; Williamson, S.K.; Findlay, B.P.; Pitot, H.C.; Alberts, S. Randomized controlled trial of reduced-dose bolusfluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 2006, 24(21), 3347-3353.
4. Sørbye, H.; Glimelius, B.; Berglund, A.; Fokstuen, T.; Tveit, K.M.; Braendengen, M.;Evgreid, D.; Dahl,O.Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2004, 22(1), 31-38.
5. Ferrara, N.; Gerber, H.P.; LeCouter, J. The biology of VEGF and its receptors. Nat Med 2003, 9(6), 669-676.
6. Kabbinavar, F.; Hurwitz, H.I.; Fehrenbacher, L.; Meropol, N.J.; Novotny, W.F.; Lieberman, G.; Griffing, S.; Bergsland, E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 21(1), 60-65.
7. Kabbinavar, F.F.; Schulz, J.; McCleod, M.; Patel, T.; Hamm, J.T.; Hecht, J.R.; Mass, R.; Perrou, B.; Nelson, B.; Novotny, W.F. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005, 23(3), 3697-3705.
8. Kabbinavar, F.F.; Hambleton, J.; Mass, R.D.; Hurwitz, H.I.; Bergsland, E.; Sarkar, S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005, 23(16), 3706-3712.
9. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350(23), 2335-2342.
10. Fuchs, C.; Marshall, J.; Mitchell, E.; Wierzbicki, R.; Ganju, V.; Jeffery, M.; Schulz, J.; Richards, D.; Soufi-Mahjoubi, R.; Wang, B.; Barrueco, J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007, 25(30), 4779-4786.
11. The National Comprehensive Cancer Network. Clinical practice guidelines in oncology: colon cancer, version 1.2008. Available at http://www.nccn.org/ professionals/physician gls/PDF/colon.pdf
12. Tournigand, C.; Andŕ e, T.; Achille, E.; Lledo, G.; Flesh, M.; Mery- Mignard, D.; Quinaux, E.; Couteau, C.; Buyse, M.; Ganem, G.; Landi, B.; Colin, P.; Louvet, C.; de Gramont, A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004, 22(2), 229-237.
13. Ulrich-Pur, H.; Kornek, G.V.; Fiebiger, W.; Gedlicka, C.; Raderer, M.; Lenauer, A.; Depisch, D.; Lang, F.; Pidlich, J.; Scheithauer, W. Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy. Ann Oncol 2001, 12(9), 1269-1272.
14. Stickel, F.; J̈ungert, B.; Brueckl, V.; Schirner, I.; Brueckl, W.M.; M̈annlein, G.; Hegewald, J.; M̈uhldorfer, S.; Bittorf, B.; Hohenberger, W.; Hahn, E.G.; Wein, A. Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as secondand third-line treatment in patients with colorectal cancer pretreated with AIO plus oxaliplatin. Anticancer Drugs 2003, 14(9), 745-749. (Pubitemid 37357700)
15. Recchia, F.; Saggio, G.; Nuzzo, A.; Lalli, A.; Lullo, L.D.; Cesta, A.; Rea, S. Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX. Br J Cancer 2004, 91(8), 1442-1446.
16. Souglakos, J.; Vardakis, N.; Androulakis, N.; Kakolyris, S.; Kouroussis, Ch.; Mavroudis, D.; Pallis, A.; Agelaki, S.; Kalbakis, K.; Georgoulias, V. Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients withmetastatic colorectal cancer: a phase II trial. J BUON 2005, 10(1), 47-52.
17. Mabro, M.; Artru, P.; Andre, T.; Flesch, M.; Maindrault-Goebel, F.; Landi, B.; Lledo, G.; Plantade, A.; Louvet, C.; deGramount, A. A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients. Br J Cancer 2006, 94(6), 1287-1292.
18. Sørbye, H.; Berglund, A.; Tveit, K.M.; Ogreid, D.; Wanderas, E.H.; Wentzel-Larsen, T.; Dahl, O.; Glimelius, B. Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer. Acta Oncol 2007, 46(7), 982-988.
19. Giantonio, B.J.; Catalano, P.J.; Meropol, N.J.; O'Dwyer, P.J.; Mitchell, E.P.; Alberts, S.R.; Schwartz, M.A.; Benson, A.B., 3rd.; Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007, 25(12), 1539-1544.
20. Cohen, M.H.; Gootenberg, J.; Keegan, P.; Pazdur, R. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 2007, 12(3), 356-361.
21. Therasse, P.; Arbuck, S.G.; Eisenhauer, E.A.;Wanders, J.; Kaplan, R.S.; Rubinstein, L.; Verweij, J.; Van Glabbeke, M.; van Oosterom, A.T.; Christian, M.C.; Gwyther, S.G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3), 205-216.
22. National Cancer Institute Common Toxicity Criteria (NCI-CTC) v2.0. http://ctep.info.nih.gov/reporting/ctc.html
23. Kaplan, E.L.; Meier, P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958, 53, 457-481.